2fcg: Difference between revisions
No edit summary |
No edit summary |
||
Line 1: | Line 1: | ||
==Solution structure of the C-terminal fragment of human LL-37== | ==Solution structure of the C-terminal fragment of human LL-37== | ||
<StructureSection load='2fcg' size='340' side='right' caption='[[2fcg]], [[NMR_Ensembles_of_Models | 20 NMR models]]' scene=''> | <StructureSection load='2fcg' size='340' side='right'caption='[[2fcg]], [[NMR_Ensembles_of_Models | 20 NMR models]]' scene=''> | ||
== Structural highlights == | == Structural highlights == | ||
<table><tr><td colspan='2'>[[2fcg]] is a 1 chain structure. Full experimental information is available from [http://oca.weizmann.ac.il/oca-bin/ocashort?id=2FCG OCA]. For a <b>guided tour on the structure components</b> use [http://oca.weizmann.ac.il/oca-docs/fgij/fg.htm?mol=2FCG FirstGlance]. <br> | <table><tr><td colspan='2'>[[2fcg]] is a 1 chain structure. Full experimental information is available from [http://oca.weizmann.ac.il/oca-bin/ocashort?id=2FCG OCA]. For a <b>guided tour on the structure components</b> use [http://oca.weizmann.ac.il/oca-docs/fgij/fg.htm?mol=2FCG FirstGlance]. <br> | ||
Line 22: | Line 22: | ||
__TOC__ | __TOC__ | ||
</StructureSection> | </StructureSection> | ||
[[Category: Large Structures]] | |||
[[Category: Li, X]] | [[Category: Li, X]] | ||
[[Category: Wang, G]] | [[Category: Wang, G]] |
Revision as of 13:48, 18 March 2020
Solution structure of the C-terminal fragment of human LL-37Solution structure of the C-terminal fragment of human LL-37
Structural highlights
Function[CAMP_HUMAN] Binds to bacterial lipopolysaccharides (LPS), has antibacterial activity.[1] [2] Publication Abstract from PubMedTo understand the structure and activity relationship of human LL-37, a series of peptide fragments was designed. The N-terminal fragment, LL-37(1-12), was not active, while the C-terminal fragment, LL-37(13-37), killed Escherichia coli, as well as drug-sensitive and drug-resistant cancer cells. A 13-residue core antibacterial and anticancer peptide, corresponding to residues 17-29 of LL-37, was identified based on total correlated spectroscopy by trimming nonessential regions (TOCSY-trim). Because LL-37 acts on bacterial membranes, three-dimensional structures of its fragments were determined in micelles by NMR, including structural refinement by natural abundance 15N and 13C chemical shifts. Aromatic-aromatic interactions in the N-terminal fragment were proposed to be essential for LL-37 aggregation. The LL-37 core peptide adopts a similar structure in the micelles of SDS or dioctanoyl phosphatidylglycerol. This structure is retained in the C-terminal fragment LL-37(13-37) and very likely in intact LL-37 based on peptide-aided signal assignments. The higher antibacterial activity of the LL-37 core peptide than aurein 1.2 was attributed to additional cationic residues. To achieve selective membrane targeting, D-amino acids were incorporated into LL-37(17-32). While the D-peptide showed similar antibacterial activity to the L-diastereomer, it lost toxicity to human cells. Structural analysis revealed hydrophobic defects in the new amphipathic structure of the D-peptide, leading to a much shorter retention time on a reversed-phase HPLC column. It is proposed that hydrophobic defects as a result of incoherent hydrophobic packing provide a structural basis for the improvement in cell selectivity of the LL-37 fragment. Solution structures of human LL-37 fragments and NMR-based identification of a minimal membrane-targeting antimicrobial and anticancer region.,Li X, Li Y, Han H, Miller DW, Wang G J Am Chem Soc. 2006 May 3;128(17):5776-85. PMID:16637646[3] From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine. References
|
|